|Tested species reactivity||Hamster, Human, Mouse, Primate, Rat|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG2b|
|Immunogen||Synthetic peptide corresponding to amino-terminal residues of human beta-Actin, conjugated to KLH.|
|Contains||0.03% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||1/200 - 1/400|
|Immunofluorescence (IF)||1/200 - 1/1000|
|Western Blot (WB)||1/500 - 1/2000|
|Immunohistochemistry (Paraffin) (IHC (P))||See 1 publications below|
MA5-15452 targets beta-Actin in FACS, IF, and WB applications and shows reactivity with Hamster, Human, mouse, Non-human primate, and Rat samples.
The MA5-15452 immunogen is synthetic peptide corresponding to amino-terminal residues of human beta-Actin, conjugated to KLH.
MA5-15452 detects beta-Actin which has a predicted molecular weight of approximately 42kDa.
This gene encodes one of six different actin proteins. Actins are highly conserved proteins that are involved in cell motility, structure, and integrity. This actin is a major constituent of the contractile apparatus and one of the two nonmuscle cytoskeletal actins.
An Antibody-Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies.
MA5-15452 was used in immunohistochemistry - paraffin section to discuss the use of antibody-drug conjugates to deliver cytotoxic agents to tumors
|Asundi J,Crocker L,Tremayne J,Chang P,Sakanaka C,Tanguay J,Spencer S,Chalasani S,Luis E,Gascoigne K,Desai R,Raja R,Friedman BA,Haverty PM,Polakis P,Firestein R||Clinical cancer research : an official journal of the American Association for Cancer Research (21:3252)||2015|
ACTB; actin, beta; actin, cytoplasmic 1; Atcb; beta cytoskeletal actin; beta-actin; cytoplasmic beta-actin; PS1TP5-binding protein 1; PS1TP5BP1
ACTB; Actx; beta-actin; BRWS1; E430023M04Rik; PS1TP5BP1